Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04725838
Other study ID # UPGRADE
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 29, 2021
Est. completion date January 29, 2025

Study information

Verified date September 2022
Source Celéri Health, Inc.
Contact Jean Myers
Phone 215-828-9070
Email jean@celerihealth.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 25 centers in the United States with up to 600 participants enrolled.


Description:

This clinical investigation is a prospective, observational, open-label, non-randomized, multi-center study. It is designed to collect clinical follow-up data on Differential Target Multiplexed (DTM®) programming that is available in Medtronic's Intellis™ and Vanta™ spinal cord stimulators, which has shown superiority to conventional programming parameters in a randomized controlled trial (NCT03606187). Participants currently implanted with a permanent neurostimulation system, whom are planned for conversion to DTM® programming as well as newly identified participants planned to undergo a trial of neurostimulation using DTM® will be eligible to participate in this study. Data will be collected at baseline prior to DTM® programming exposure. Participants who continue to meet eligibility criteria and have had their implanted DTM programming activated will enter a follow-up period for up to 24 months, where participant self-reported questionnaires will be assessed each month with study visits to occur at months 12 and 24. Throughout the study, objective functional data will be collected automatically as part of the Medtronic device interrogation.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date January 29, 2025
Est. primary completion date January 29, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participant must provide written informed consent prior to any clinical study-related procedure. 2. Participant is at least 18 years (or the minimum age required by local law to consent for participation in a clinical investigation) or older at the time of enrollment. 3. Participant has a permanent Medtronic Intellis™ neurostimulation system implanted or is planning to be implanted with a Medtronic Intellis™ or Vanta™ neurostimulation system. 4. Participant has access to an iPhone or Android capable device and/or computer with regular internet access for the purposes of electronically completing web-based participant self-reported questionnaires via SMS text or email. Exclusion Criteria: 1. Participant is unable to provide written informed consent or to comply with study-related requirements, procedures, and visits. 2. Participant is a profound responder for all pain areas to existing neurostimulation therapy (=80% reported relief). 3. Participant is enrolled, or intends to participate, in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) which could confound the results of this trial as determined by the investigator. 4. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements. 5. Participant is pregnant or nursing.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Medtronic Intellis™ and Vanta™
Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems

Locations

Country Name City State
United States Neuroversion Anchorage Alaska
United States Millennium Pain Center (National Spine and Pain Centers - Bloomington, IL) Bloomington Illinois
United States Florida Pain Medicine - Brandon Brandon Florida
United States NuVation Pain Group - Buena Park Buena Park California
United States Carolinas Research Institute - Mallard Creek Charlotte North Carolina
United States Jax Spine & Pain Centers - Fleming Island Fleming Island Florida
United States North Texas Orthopedics & Spine Center- Keller/Alliance Fort Worth Texas
United States North Texas Orthopedics & Spine Center - Grapevine Grapevine Texas
United States Comprehensive and Interventional Pain Management Henderson Nevada
United States Premier Pain Treatment Institute - Hillsboro Hillsboro Ohio
United States Carolinas Research Institute - Huntersville Huntersville North Carolina
United States Jax Spine & Pain Centers - Jacksonville Jacksonville Florida
United States Jax Spine & Pain Centers - UF North Jacksonville Florida
United States NuVation Pain Group - Los Angeles Los Angeles California
United States Premier Pain Treatment Institute - Loveland Loveland Ohio
United States Premier Pain Treatment Institute - Mt. Orab Mount Orab Ohio
United States Oklahoma Pain Physicians - Norman Norman Oklahoma
United States Oklahoma Pain Physicians - Oklahoma City Oklahoma City Oklahoma
United States Spine and Sports Specialty Medical Group Orange California
United States Desert Sky Spine & Sports Medicine Oro Valley Arizona
United States National Spine and Pain Centers - National Harbor (Oxon Hill) Oxon Hill Maryland
United States National Spine and Pain Centers - Pikesville, MD Pikesville Maryland
United States Oklahoma Pain Physicians - Purcell Purcell Oklahoma
United States Florida Spine & Pain Specialists Riverview Florida
United States Spine & Nerve Diagnostic Center - Roseville Roseville California
United States Jax Spine & Pain Centers -St. Augustine Saint Augustine Florida
United States Desert Sky Spine & Sports Medicine Sierra Vista Arizona
United States Northwest Pain Care Spokane Washington
United States Precision Spine Care Tyler Texas
United States National Spine and Pain Centers - The Pain Management Center - Voorhees Voorhees New Jersey
United States Centurion Spine & Pain Centers (Jax Spine) Waycross Georgia
United States Florida Pain Medicine - Wesley Chapel Wesley Chapel Florida
United States Valley Pain Consultants Winchester Virginia
United States National Spine and Pain Centers - Winter Park, FL Winter Park Florida

Sponsors (2)

Lead Sponsor Collaborator
Celéri Health, Inc. Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the Pain Impact Score as measured by the PROMIS-29 before and after introduction of Differential Target Multiplexed (DTM®) stimulation programming in a real-world population. 24 months
Secondary To characterize the responder rate for pain by pain area per Percent Pain Relief for DTM-SCS® compared to participant baseline treatment. 24 months
Secondary To characterize the responder rate for pain by pain area per Numeric Rating Scale for DTM-SCS® compared to participant baseline treatment. 24 months
Secondary To evaluate the longitudinal characterization of objective posture and activity measures. Time spent in each activity/position (Intellis™ device data) 24 months
Secondary To characterize Patient Global Impression of Change (PGIC) with neurostimulation. 24 months
Secondary To evaluate the performance of the DTM® pre-programming questionnaire in predicting outcome of DTM-SCS® programming. 24 months
Secondary To characterize the neuropathic pain quality using PROMIS-Neuropathic Pain Quality (PROMIS-PQ-Neuro) before and after treatment. 24 months
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain

External Links